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ABSTRACT
Background The metabolic syndrome (MetS) may
contribute to increased cardiovascular risk in systemic
lupus erythematosus (SLE). We aimed to examine the
association of demographic factors, lupus phenotype and
therapy exposure with the presence of MetS.
Methods The Systemic Lupus International Collaborating
Clinics Registry for Atherosclerosis inception cohort
enrolled recently diagnosed (<15 months) SLE patients
from 30 centres across 11 countries from 2000. Clinical,
laboratory and therapeutic data were collected according
to a standardised protocol. MetS was defined according
to the 2009 consensus statement from the International
Diabetes Federation. Univariate and backward stepwise
multivariate logistic regression were used to assess the
relationship of individual variables with MetS.
Results We studied 1686 patients, of whom 1494
(86.6%) had sufficient data to determine their MetS
status. The mean (SD) age at enrolment and disease
duration was 35.2 years (13.4) and 24.1 weeks (18.0),
respectively. MetS was present at the enrolment visit in
239 (16%). In backward stepwise multivariable regression
analysis, higher daily average prednisolone dose (mg) (OR
1.02, 95% CI 1.00 to 1.03), older age (years) (OR 1.04,
95% CI 1.03 to 1.06), Korean (OR 6.33, 95% CI 3.68 to
10.86) and Hispanic (OR 6.2, 95% CI 3.78 to 10.12)
ethnicity, current renal disease (OR 1.79, 95% CI 1.14 to
2.80) and immunosuppressant use (OR 1.81, 95% CI
1.18 to 2.78) were associated with MetS.
Conclusions Renal lupus, higher corticosteroid doses,
Korean and Hispanic ethnicity are associated with MetS in
SLE patients. Balancing disease control and minimising
corticosteroid exposure should therefore be at the forefront
of personalised treatment decisions in SLE patients.
INTRODUCTION
Women with systemic lupus erythematosus (SLE)
have a greater than fivefold increased risk of clinical
coronary heart disease (CHD) events, rising to a
50-fold increase in younger patients.1 Patients with
SLE also have an increased burden of subclinical
atherosclerosis, as measured by coronary calcium,
carotid plaque, arterial stiffness and endothelial
dysfunction.2–5 Although classic Framingham risk
factors are more prevalent in SLE,6 they do not
fully explain this excess CHD risk.7
The metabolic syndrome (MetS) is a clustering
of related CHD risk factors that reflects central
obesity and insulin resistance. MetS is associated
with an increased risk of developing both type 2
diabetes mellitus and atherosclerosis in the general
population.8 While there have been several histor-
ical definitions,9 a recent consensus statement pro-
posed a harmonised definition to aid research and
permit comparisons between cohorts and popula-
tions to be made.10 The precise role of the MetS in
CHD risk prediction remains subject to intense
debate;11–14 however, it is recognised to be a useful
clinical tool to identify patients who may warrant
more focused CHD risk assessment.15
In small cross-sectional studies, MetS is more
common in SLE patients,16 and as such may contrib-
ute to the CHD risk in SLE. In addition, the actual
MetS phenotype in SLE may also differ.17–20 Similar
rates of central obesity in SLE compared to controls
have been observed, but differences in the prevalence
of hypertension and hypertriglyceridaemia suggest
that lupus may drive a more inflammatory MetS
phenotype. Lupus features implicated in MetS include
inflammatory disease activity, disease damage and
therapeutic exposures, particularly to corticosteroids,
although studies to date have been inconsistent.16
Determining the contribution of the SLE phenotype
and therapeutic exposures to the development of
MetS in SLE would yield important insights into the
pathophysiology of cardiovascular risk and guide
better stratification of CHD risk in these patients.
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The Systemic Lupus International Collaborating Clinics
(SLICC) group has developed an international registry of
patients with newly diagnosed SLE to facilitate prospective,
longitudinal studies of risk factors for the development of ath-
erosclerosis in SLE. The aim of the present cross-sectional study
was to investigate the prevalence of, and factors associated
with, MetS in patients with SLE at enrolment into the SLICC
inception cohort.
METHODS
SLICC registry for atherosclerosis
SLICC comprises 30 centres from 11 countries in North
America, Europe and Asia. An inception cohort was recruited
between 2000 and 2009 to investigate risk factors for athero-
sclerosis in SLE. Data were submitted to the coordinating
centre at the University of Toronto at enrolment, and patients
were reviewed annually in their local centre. Laboratory tests
(fasting or non-fasting) necessary to evaluate disease activity,
CHD risk factors, and to define MetS were performed locally.
The study was approved by the University Health Network
Research Institute, Research Ethics Committee, Toronto,
Canada and by the institutional research ethics boards of par-
ticipating centres in accordance with the Declaration of
Helsinki’s guidelines for research in humans.
Patients
Patients were enrolled when four or more American College of
Rheumatology (ACR) classification criteria for SLE21 were
recognised. All patients were enrolled within 15 months of the
date of their diagnosis. There were no specific exclusion criteria
other than failing to meet four or more ACR criteria and being
more than 15 months since diagnosis. Clinical and laboratory
features, including CHD risk factors and therapeutic exposures,
were recorded according to a standard protocol. SLE disease
activity and damage were assessed using the SLE disease activ-
ity index (SLEDAI-2K)22 and the SLICC/ACR damage index
(SLICC-DI),23 respectively. Active nephritis was defined as:
haematuria greater than five red blood cells/high power field,
excluding other causes; pyuria greater than five white blood
cells/high power field, excluding infection; new/recent increase
of more than 500 mg/24 h protein; casts including granular or
red blood cells; or consistent renal biopsy. Nephrotic syndrome
was defined as proteinuria greater than 3 g/24 h, oedema and
increased blood pressure (BP). All patients provided written
informed consent.
Definition of MetS
MetS was defined according to the 2009 definition in the joint
interim statement from the International Diabetes Federation
Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society and
International Association for the Study of Obesity.10 This har-
monising statement requires three or more of the following five
criteria to be present: (1) elevated waist circumference (MetS
WC) using population/country-specific thresholds; (2) elevated
triglycerides (MetS TG) of 1.7 mmol/l or greater (≥150 mg/dl)
or drug therapy for hypertriglyceridaemia; (3) reduced high-
density lipoprotein (HDL) cholesterol (MetS HDL) less than
1.3 mmol/l (<50 mg/dl) in women and less than 1.0 in men or
drug therapy for reduced HDL-cholesterol; (4) elevated BP
(MetS BP) of 130/85 mm Hg or greater or drug therapy for
hypertension; and (5) elevated fasting glucose (MetS Glu) of
5.6 mmol/l or greater (≥100 mg/dl) or drug therapy for
hyperglycaemia.
Statistical analysis
SLE factors implicated in MetS development in SLE were
defined a priori. These represented inflammatory disease activ-
ity (SLEDAI-2K), disease phenotype including active renal
disease, low complement or high anti-double-stranded DNA
antibodies and therapeutic exposures including several measures
of corticosteroid exposure. All corticosteroid doses were con-
verted to milligrams (mg) of prednisolone equivalent. The
cumulative oral prednisolone dose received before enrolment (g)
was calculated for each individual. A comparison of continuous
data was performed using Wilcoxon’s rank sum test, and of cat-
egorical data using the χ2 test. Univariate logistic regression
was used to assess the relationship between the presence of
MetS at enrolment into the SLICC registry for athersclerosis
(RAS) and individual variables. Results presented are adjusted
OR and 95% CI. Analysis was adjusted for age, ethnicity and
gender. Those factors associated with MetS on univariate ana-
lysis (p<0.2) were entered into a multivariable model.
Backward stepwise multivariate logistic regression was per-
formed with significance set at 5%, resulting in a final model.
All statistical analyses were performed using STATA 10.0.
RESULTS
Patients
By 2009, 1686 patients were enrolled into SLICC–RAS.
Sufficient data were available to define the presence or absence
of MetS in 1494 (88.6%) patients, of whom 1336 (89.4%) were
women. The mean (SD) age at enrolment into the study was
35.2 years (13.4) and the mean (SD) disease duration was
24.1 weeks (18.0). There was a wide ethnic variation, reflecting
the participating centres; 660 (44.2%) were Caucasian, 240
(16.1%) were Hispanic, 228 (15.3%) were black African,
African-American or Afro-Caribbean and 303 (20.3%) were
south-east Asian. At enrolment the mean (SD) SLEDAI was 5.5
(5.4) and 287 (19.3%) had very active disease with a SLEDAI of
10 or greater (table 1).
There were 192 (11.4%) patients with insufficient data to
determine the MetS status. This group had similar demograph-
ics and SLICC-DI to the rest of the cohort. However, they had
a lower mean SLEDAI, a lower prevalence of renal disease, less
immunosuppressant use and were more likely to be receiving
antimalarial therapies. This subset also had a lower frequency
of corticosteroid exposure (see supplementary table S1, avail-
able online only).
Prevalence of MetS
MetS was present in 239/1494 (16%) patients. The individual
MetS criteria met were: MetS WC (686/1334, 48.4%), MetS BP
(686/1491, 46%), MetS TG (619/1342, 46.1%), MetS HDL
(486/822, 59.1%) and MetS Glu (271/1344, 20.2%). MetS was
more common in men than women (22.2% vs 15.2%; p=0.03)
and those with MetS were older than those without (mean
(SD) age 36.9 years (13.3) vs 34.9 years (14.7); p<0.04). Patients
of Hispanic and Korean ethnicity had the highest prevalence of
MetS, compared to the rest of the cohort (31.3% and 30.1% vs
10.3%; p<0.0001).
Factors associated with MetS at enrolment
In an age, ethnicity and gender-adjusted analysis we assessed
the strength of the relationship between the presence of MetS
and our predefined variables related to inflammation, disease
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phenotype and therapeutic exposure (table 2). SLE features
associated with MetS included active renal lupus (OR 2.87,
95% CI 2.05 to 4.02), SLEDAI-2K greater than 10 (OR 1.73,
95% CI 1.22 to 2.44) and thrombocytopenia (OR 2.10, 95% CI
1.03 to 4.29). Several corticosteroid variables showed an associ-
ation, including current oral (OR 1.53, 95% CI 1.05 to 2.25)
and past intravenous (OR 3.22, 95% CI 1.35 to 7.68) cortico-
steroid use. SLE patients with MetS received oral corticosteroids
at higher average daily doses and with higher cumulative and
peak doses compared to those without MetS. The use of
immunosuppressive agents was also associated with MetS (OR
2.21, 95% CI 1.63 to 3.00), and a negative association with
antimalarial use was observed (OR 0.51, 95% CI 0.38 to 0.67).
In a backward stepwise multivariable regression analysis,
factors independently associated with MetS were higher
average daily oral prednisolone dose (mg) (OR 1.02, 95% CI
1.00 to 1.03), older age at study entry (years) (OR 1.04, 95% CI
1.03, 1.06), Korean (OR 6.33, 95% CI 3.68 to 10.86) and
Hispanic (OR 6.2, 95% CI 3.78 to 10.12) ethnicity, active renal
lupus (OR 1.79, 95% CI 1.14 to 2.80) and immunosuppressant
use (OR 1.81, 95% CI 1.18 to 2.78). These remained unchanged
when overlapping variables (such as proteinuria and active
renal disease) were excluded. When active renal involvement
was removed from the multivariable model in favour of the
renal components scored on SLEDAI, the presence of haema-
turia became significant (OR 1.70, 95% CI 1.03 to 2.82) (with
other variables in the final model unchanged).
Exploratory analyses
We further examined the two highest risk ethnicities to explore
potential differences in SLE features or therapeutic exposures
that may influence the presence of MetS. One hundred and
sixty-five of 169 (97.6%) patients of Korean ethnicity resided
in South Korea; 192 of 240 (80%) patients of Hispanic
ethnicity resided in Mexico and 16.3% in the USA. Korean
and Hispanic patients demonstrated distinct and contrasting
MetS phenotypes compared to each other and the rest of the
cohort (table 3). Patients of Korean ethnicity had a lower preva-
lence of central obesity (MetS WC 20.1% vs 51.3%; p<0.0001)
and lower mean (SD) body mass index (BMI) (21.6 (4.3) vs 25.8
(6.1) kg/m2; p=<0.0001), but a significantly increased preva-
lence of hyperglycaemia and dyslipidaemia. Korean patients also
had more active laboratory features in the SLEDAI, such as
positive anti-dsDNA antibodies (66% vs 36.0%; p<0.001), hypo-
complementaemia (75.2% vs 33.1%; p<0.001) and thrombo-
cytopenia (11.2% vs 2.7%; p<0.001). Oral corticosteroid use in
the Korean cohort was almost universal (95.3%), although the
average daily, peak and cumulative doses were similar or lower
than the rest of the cohort.
In the Hispanic cohort, MetS was contributed to by signifi-
cantly more dyslipidaemia (MetS TG 64.3% vs 40.3%;
p<0.0001); MetS HDL (65.1% vs 52.7%; p<0.0001), despite a
similar prevalence of central obesity. Hispanic patients also had
more active renal disease at enrolment (40.4% vs 15.5%;
p<0.0001) but similar rates of both hypertension and active
serological indicators (ie, elevated anti-dsDNA antibodies and
low complement) to other ethnicities. Hispanic patients were
also exposed to higher average, peak and cumulative doses of
corticosteroids but less antimalarial agents than the rest of the
SLICC–RAS cohort (table 4).
To test whether the effect of corticosteroids was dose depend-
ent, the multivariable model was run using only current oral cor-
Table 1 Characteristics of patients at enrolment into SLICC–RAS
No of patients 1494
Age, years (mean (SD)) 35.2 (13.4)
Gender (%)
Female 1336 (89.4)
Male 158 (10.6)
Ethnicity (%)
Caucasian 660/1492 (44.2)
Black African/Afro-Caribbean 228/1492 (15.3)
SE Asian 303/1492 (20.3)
Hispanic 240/1492 (16.1)
Other 61/1492 (4.1)
Region (%)
Canada 358/1477 (24.2)
Mexico 194/1477 (13.1)
USA 374/1477 (25.3)
Asia 168/1477 (11.4)
Europe 383/1477 (25.3)
CHD risk factors (mean (SD))
BP systolic, mm Hg 119.5 (16.8)
BP diastolic, mm Hg 75.3 (11.0)
On AHT medication, % 435 (29.1)
Total cholesterol, mmol/l 4.93 (1.49)
Triglyceride, mmol/l 1.79 (1.19)
HDL-cholesterol, mmol/l 1.39 (0.60)
On lipid-lowering medication, % 171 (11.5)
Glucose, mmol/l 5.03 (1.63)
Diabetes, % 50 (3.4)
Smoker current, % 225 (15.1)
Premenopausal, % 1244 (83.3)
BMI 25.1 (5.9)
WC, cm 82.9 (14.0)
5-Year % Framingham risk
Women 0.57
Men 5.03
Disease duration, weeks (mean SD) 24.1 (18.0)
SLEDAI (mean SD) 5.5 (5.4)
SLICC/ACR-DI=0 528 (81.9%)
Disease phenotype (%)
Active renal disease 314 (22.9)
Anti-dsDNA positive 541/1347 (40.2)
Low complement 519/1349 (38.5)
Thrombocytopenia 44/1313 (3.4)
Oral CS use (median (IQR)) 1043 (69.8)
Average CS dose, mg 20 (10, 30)
Highest CS dose, mg 40 (20, 60)
Cumulative CS dose, g 2.6 (1.1, 5.0)
Pulse IV CS (%) 70/1423 (4.9)
Immunosuppressant use (%) 599/1491 (31.0)
Azathioprine 262 (43.7)
Methotrexate 104 (17.4)
Mycophenolate mofetil 98 (16.4)
IV cyclophosphamide 95 (15.9)
Ciclosporin 21 (3.5)
Other 19 (3.2)
Antimalarial use (%) 971 (65.0)
ACR, American College of Rheumatology; AHT, antihypertensive; BMI, body mass
index; BP, blood pressure; CHD, coronary heart disease; CS, corticosteroid; DI,
damage index; HDL, high-density lipoprotein; IV, intravenous; RAS, Registry
for Atherosclerosis; SLEDAI, systemic lupus erythematosus disease activity
index; SLICC, Systemic Lupus International Collaborating Clinics; WC, waist
circumference.
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Table 2 Significant factors associated with MetS at enrolment into SLICC–RAS in age, ethnicity and gender-adjusted analyses
MetS
Yes No p Value OR (95% CI)
Current CS (%) 193/239 (80.8) 8250/1255 (67.7) <0.001 1.53 (1.05 to 2.25)
Average CS dose, mg (median (IQR)) 30 (15, 45) 20 (10, 30) <0.001 1.02 (1.01 to 1.04)
Highest CS dose, mg (median (IQR)) 50 (30, 60) 30 (20, 50) <0.001 1.00 (1.00 to 1.01)
Cumulative CS dose, g (median (IQR)) 3.1 (1.5, 5.4) 2.3 (1.0, 4.0) 0.006 1.05 (1.00 to 1.09)
Past IV CS (%) 18/230 (7.8) 52/1193 (4.4) 0.03 3.22 (1.35 to 7.68)
Antimalarial (%) 123/239 (51.5) 848/1255 (67.6) <0.001 0.51 (0.38 to 0.67)
Immunosuppressant (%) 140/238 (58.8) 459/1253 (36.6) <0.001 2.21 (1.63 to 3.00)
SLICC-DI ≥1 (%) 26/95 (27.4) 91/550 (16.6) 0.01 1.99 (1.16 to 3.40)
SLEDAI-2K (mean (SD)) 6.79 (6.19) 5.24 (5.25) <0.001 1.05 (1.02 to 1.07)
SLEDAI≥10 (%) 66/239 (27.6) 221/1252 (17.7) 0.001 1.73 (1.22 to 2.44)
High anti-dsDNA (%) 101/216 (46.8) 440/1131 (38.9) 0.03 1.32 (1.00 to 1.82)
Thrombocytopenia (%) 14/206 (6.8) 30/1107 (2.7) 0.003 2.10 (1.03 to 4.29)
Leucopenia (%) 7/203 (3.5) 92/1108 (8.3) 0.02 0.33 (0.14 to 0.75)
Active renal disease (%) 94/239 (39.3) 220/1255 (17.5) <0.001 2.87 (2.05 to 4.02)
Past renal disease (%) 22/239 (9.2) 69/1255 (5.5) 0.03 1.67 (1.00 to 2.88)
Variables reflect current exposures, recorded at enrolment.
CS, corticosteroid; DI, damage index; IV, intravenous; MetS, metabolic syndrome; RAS, Registry for Atherosclerosis; SLEDAI, systemic lupus erythematosus disease activity
index; SLICC, Systemic Lupus International Collaborating Clinics.
Table 3 Characteristics of patients of Korean and Hispanic ethnicity compared to all other ethnicities
Korean p Value* Hispanic p Value† Other ethnicities
No of patients 169 240 1085
Age, years (mean (SD)) 28.8 (9.7) <0.0001 29.2 (10.3) <0.0001 37.5 (14.0)
Gender (%)
Female 150 (88.8) 0.90 218 (90.8) 0.45 968 (89.2)
Male 19 (11.2) 0.90 22 (9.2) 0.45 117 (10.8)
MetS (%) 52 (30.8) <0.0001 72 (31.3) <0.0001 112 (10.3)
MetS phenotype (%)
MetS WC 33/164 (20.1) <0.0001 129/228 (56.6) 0.15 483/942 (51.3)
MetS BP 74 (43.8) 0.63 117 (48.8) 0.40 495/1082 (45.8)
MetS TG 100/153 (65.4) <0.0001 108/168 (64.3) <0.0001 411/1021 (40.3)
MetS HDL 110/144 (76.4) <0.0001 97/149 (65.1) 0.007 279/529 (52.7)
MetS Glu 45/168 (26.8) 0.04 41/236 (17.4) 0.42 185/940 (19.7)
BMI (mean(SD)) 21.6 (4.3) <0.0001 24.5 (5.0) 0.002 25.8 (6.1)
WC, cm (mean (SD)) 74.7 (8.1) <0.0001 82.9 (10.9) 0.17 84.3 (14.9)
Disease duration, weeks (mean SD)) 18.5 (15.9) <0.0001 23.2 (16.9) 0.15 25.1 (18.4)
SLEDAI (mean SD)) 7.45 (6.09) <0.0001 6.46 (5.75) <0.0001 5.0 (5.2)
SLICC/ACR-DI (mean (SD)) 0.24 (0.69) 0.50 0.28 (0.69) 0.87 0.30 (0.74)
Disease phenotype (%)
Active renal disease 49 (29.0) <0.0001 97 (40.4) <0.0001 168 (15.5)
Anti-dsDNA positive 105/159 (66.0) <0.0001 84/211 (39.8) 0.30 352/977 (36.0)
Low complement 121/161 (75.2) <0.0001 74/208 (35.6) 0.46 324/980 (33.1)
Thrombocytopenia 16/143 (11.2) <0.0001 2/210 (1.0) 0.13 26/960 (2.7)
Medication (median (IQR))
Oral CS, %* 161 (95.3) <0.0001 211 (87.9) <0.0001 671 (61.8)
Average CS dose, mg 20 (10, 35) 0.26 30 (15, 42.5) <0.0001 20 (10, 30)
Highest CS dose, mg 30 (15, 55) 0.07 50 (30, 60) <0.0001 40 (20, 60)
Cumulative CS dose, g 1.4 (0.4, 3.1) <0.0001 3.9 (1.8, 6.2) <0.0001 2.5 (1.2, 4.8)
Pulse intravenous CS, % 26 (15.4) <0.0001 5/223 (2.2) 0.26 39/1031 (3.8)
Immunosuppressant (%) 86 (50.9) <0.0001 146 (60.8) <0.0001 367/1082 (33.9)
Antimalarial (%) 120 (71.0) 0.29 125 (52.1) <0.0001 705 (65.0)
*Korean versus all other (non-Hispanic) ethnicities.
†Hispanic versus all other (non-Korean) ethnicities.
ACR, American College of Rheumatology; BMI, body mass index; BP, blood pressure; CS, corticosteroid; DI, damage index; Glu, glucose; HDL, high-density lipoprotein; MetS,
metabolic syndrome; SLEDAI, systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating Clinics; TG, triglycerides; WC, waist
circumference.
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ticosteroid use (yes/no), with dose-related variables excluded. In
this model, current corticosteroid use was not significantly asso-
ciated with MetS although past intravenous corticosteroid use
was (OR 2.45, 95%CI 1.01 to 5.97), suggesting that increasing
corticosteroid doses have a greater impact on MetS susceptibility
than simple exposure status. Immunosuppressive therapies were
not predicted a priori to be mechanistically involved in MetS
development but rather act as a marker of disease severity,
higher disease activity and/or corticosteroid use. The majority of
patients receiving immunosuppressive therapies were also receiv-
ing oral corticosteroids (91.5%), and at higher doses than those
not on immunosuppressive the-rapies. Immunosuppressant
users also had higher SLEDAI and SLICC-DI indices (see
supplementary table S2, available online only). However, use of
immunosuppressive therapies remained a significant predictor of
MetS even after adjusting for all clinically correlating factors,
such as SLEDAI, renal disease and corticosteroid use/dose (fully
adjusted OR 2.15, 95%CI 1.15 to 4.00).
Finally, those with renal involvement had more hypertension
(MetS BP 72.9% vs 38.8%; p<0.0001) and hypertriglyceridae-
mia (MetS TG 74.1% vs 38.8%; p<0.0001) than those without
renal lupus. Central obesity parameters (BMI and MetS WC)
were, however, lower in those with renal disease, despite signifi-
cantly higher corticosteroid exposures (eg, median (IQR)
average oral prednisolone dose 30 mg (20, 50) vs 16 mg (10,
30)) (see supplementary table S3, available online only).
DISCUSSION
We report that MetS was common (16%) in SLE despite our
cohort being young, predominantly female and early in the
course of their disease. The relatively high prevalence of MetS
at enrolment suggests that the metabolic derangements that
contribute to long-term CHD risk characterised by MetS
appear early in the course of the disease. Smaller studies of
established lupus cohorts have reported MetS rates of 18–
32%, which were consistently higher than control popula-
tions.16 For example, Parker et al17 found a prevalence of 30%
in a UK SLE cohort, compared to 20% in controls, and Sabio
et al18 reported a prevalence of 20%, compared to 13% in con-
trols. These results support the hypothesis that rapid control
of inflammatory disease activity with the lowest doses of cor-
ticosteroid possible is likely to be beneficial to long-term car-
diovascular risk. The role of inflammation in the development
of atherosclerosis has been increasingly recognised,24 and SLE
is associated with higher circulating levels of high sensitivity
C-reactive protein, interleukin 18 and tumour necrosis factor
α, which are associated with insulin resistance and endothe-
lial dysfunction and have been implicated in the development
of CHD in the general population.16 25 Long-term and high-
dose corticosteroid use is associated with the pro-atherogenic
metabolic disturbances characterised by MetS,26 27 and the
weight of evidence in SLE suggests they are pro-atherogenic.
Others have, however, suggested that their anti-inflammatory
activity in lupus may exert an atheroprotective role.4 The
present study suggests that in early disease, higher doses of
corticosteroids play a pivotal role in the development of
MetS.
The strong association of MetS with Korean and Hispanic
ethnicities partly reflects a higher background population preva-
lence of MetS. In 2006 a Mexican study found the prevalence
of MetS in adults was 37–50%, depending on the definition
used,28 and 24–36% in adults aged 20–39 years. Similarly, the
San Antonio Heart Study demonstrated that people of Mexican
Hispanic descent had a higher prevalence of MetS than
Caucasian individuals, an observation especially pronounced in
women (30.9% vs 16.8%).29 A recent study of South Korean
adults described a MetS prevalence in women of 16–31%
depending on the definition used, with low levels of central
obesity, as we found in our study.30 While there is therefore
variability in the background prevalence of MetS, MetS
remains more prevalent in SLE than controls.16 The ethnic gra-
dient may therefore reflect an increased susceptibility to MetS
and enhanced sensitivity to the adverse effects of inflammation
and corticosteroid exposure in Korean and Hispanic patients.
There were, however, important differences in the MetS pheno-
type observed in these two subsets, as well as differences in the
clinical and inflammatory pattern of disease observed to be
associated with MetS. Whether these differences translate into
a differential effect on future cardiovascular endpoints is the
subject of prospective study.
Antimalarial agents showed a significant negative association
with MetS on univariate analysis; however, this did not remain
significant in our multivariable model. A protective effect of
antimalarial use against MetS has been demonstrated by other
groups with more stable, mild disease.18 31 Our study included
recently diagnosed patients with a shorter exposure to the drug
in the context of a more severe, active disease. It will be of
interest to observe how longer exposure to antimalarial agents
in the context of disease stabilisation will influence the MetS
phenotype over time in this cohort. The significant association
between immunosuppressant use and MetS may represent con-
founding, an indication of disease severity rather than mediat-
ing metabolic derangement. However, the relationship persists
even after adjusting for all measured potential confounders
(such as SLEDAI and corticosteroid use). This suggests that
either immunosuppressive therapies have direct adverse meta-
bolic effects, or there is residual confounding related to inad-
equately measured exposures, such as disease activity. Apart
from ciclosporin A, immunosuppressive therapies commonly
used in SLE are not associated with metabolic derangements,32
and may play a role in preventing atherosclerosis.33 34
Therefore, immunosuppressant use is likely to reflect residual
confounding, and additional biomarkers and/or indices of
disease activity may improve the estimation of exposure to sys-
temic inflammation.
This is the largest study to date examining MetS in SLE and
has many advantages over previous studies. The cohort is
young, with a range of disease activity that allows us to
explore more effectively the impact of inflammation on MetS
development. We also studied an international cohort recruited
from 11 countries with a range of ethnicities, and therefore the
results can be generalised to a range of populations. Our data
also included a breadth of corticosteroid data, allowing us to
Table 4 Multivariable model of predictors of MetS at enrolment
Variable OR (95% CI)
Average corticosteroid dose, mg/day 1.02 (1.00 to 1.03)
Age, years 1.04 (1.03 to 1.06)
Korean ethnicity 6.33 (3.68 to 10.86)
Hispanic ethnicity 6.20 (3.78 to 10.12)
Active renal disease 1.79 (1.14 to 2.80)
Immunosuppression use* 1.81 (1.18 to 2.78)
Variables reflect current exposures, recorded at enrolment.
Includes azathioprine, mycophenolate mofetil, cyclophosphamide, ciclosporin,
methotrexate.
MetS, metabolic syndrome.
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explore their effects in more detail. Finally, the prospective
nature of the cohort limits many potential sources of bias asso-
ciated with retrospective studies.
The analysis does, however, have several limitations. First,
there are missing MetS data on 11.4% of the cohort. While the
demographics of this cohort are broadly similar they appear to
have less severe disease, which may bias the analysis towards
disease severity markers. Our data may therefore overestimate
the true prevalence of MetS in this population. The most
common missing variable was HDL-cholesterol, which was not
universally performed locally in all centres. Second, a cross-
sectional study is not the ideal study design to dissect the inter-
play between inflammation, corticosteroid exposure and MetS,
although it can provide important data with which to inform
prospective studies. Future work will examine how these
factors influence MetS over time and investigate the influence
of genetic factors on MetS prevalence and susceptibility.
Finally, the use of MetS as a CHD risk prediction tool for
adverse cardiovascular events has yet to be validated in SLE and
the SLICC–RAS cohort is an ideal setting in which to examine
this further.
Our study confirms that MetS is common in young patients
with recently diagnosed SLE. This clustering of CHD risk
factors and the observed ethnic variation in MetS susceptibility
should help inform risk stratification in the management of
early disease. MetS is associated with a more severe disease
phenotype and higher doses of corticosteroids, therefore balan-
cing disease control while minimising corticosteroid exposure
should be at the forefront of personalised treatment decisions
in these patients.
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Correction
Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in
systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis
2013;72:1308–14.
A statistical error occurred in the above manuscript. On routine review of the analysis, the
authors have uncovered a statistical error in their original baseline analysis that has resulted in
an error in the attribution of metabolic syndrome (MetS) status to individuals in the cohort,
such that a number of individuals have been misclassified by the algorithm reported. The error
relates to how the authors used the coding commands in Stata for handling missing data. The
authors’ intention was to count the total number of MetS variables present in each individual
and to allow patients with missing data to be included if they had sufficient data points to make
a determination of their status. Instead, the command the authors originally used (‘total’)
resulted in patients with any missing data being erroneously assigned a zero total for MetS com-
ponents present (instead of the true number (if ≥3) or a missing status (if ≤2). This resulted in
both an underestimation of the true prevalence and individuals being erroneously included in
the experimental group when they should have been excluded, and thus a larger denominator
group. The authors’ initial manual checks of the data failed to identify this error.
Correction of this error (using the command ‘rowtotal’) has resulted in a reduced cohort size
and an overall increase in the number of patients classified as having MetS in the cohort (now
38.2% as opposed to 16% as originally reported). The prevalence estimates in all racial/ethnic
subsets are therefore higher and the estimate for patients of African ancestry is particularly
affected, such that the authors now report a high prevalence in this population (55.7%).
Although the point estimates in the multivariate analysis of factors associated with MetS have
changed, the actual factors remain very similar to the published multivariate model (see table
A) and the authors’ discussion of the impact of disease activity and exposure to steroids remains
unchanged.
In summary, the estimated prevalence of MetS in this cohort is now higher than that origin-
ally reported. The multivariate model has as a result of this changed, but remains similar to
the authors’ original report. Overall the key message of this paper remains the same in that
“the observed ethnic variation in MetS susceptibility should help inform risk stratification in
management of early disease. MetS is associated with a more severe disease phenotype and
higher doses of corticosteroids, therefore balancing disease control while minimising cortico-
steroid exposure should be at the forefront of personalised treatment decisions in these
patients”.
Updated tables and supplementary tables, as well as a revised abstract that summarises the
corrected results accurately, are available online as a data supplement.
The authors profoundly apologise for this error and feel it is important to communicate
this to the research community in the interests of accuracy and scientific validity.
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